Cargando…
Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
A subset of renal cell carcinoma (RCC) patients has been shown to respond to anti-EGFR therapy. As KRAS and BRAF mutations are associated with poor response to anti-EGFR therapy in some cancers, it has been suggested that screening for KRAS and BRAF mutations in RCC may be a promising strategy to id...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Codon Publications
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345528/ https://www.ncbi.nlm.nih.gov/pubmed/28326248 http://dx.doi.org/10.15586/jkcvhl.2014.10 |